N/A N=42 Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants Who Responded — 7; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Phase 2 N=42 Topical Steroid Treatment for Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Phase 3 N=318 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
Eosinophilic Esophagitis (EoE)
Primary: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) — 1; 113; 104; 100 Participants — p=<0.001
N/A N=50 Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
Phase 3 N=572 Reflux Esophagitis Phase III Study (Initial Treatment)
Reflux Esophagitis
Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…
Phase 4 N=16 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Peak Esophageal Eosinophil Count — 57.3; 71.3 Peak # of eosinophils counted per field
Phase 2 N=308 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) — 10; 19; 14; 16 Participants — p=0.001
N/A N=21 Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Measurement of Eosinophilic Degranulating Protein Concentration — 456.5 ng/mL
Phase 3 N=564 Reflux Esophagitis Phase III Study (Maintenance Treatment)
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
N/A N=25 Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Tissue Eosinophil Counts — 89; 11 # of eosinophils per high-power field
Phase 2 N=32 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Improvement of Espohageal Eosinophilia — 13; 0 Participants
Phase 2 N=119 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants Who Were Histologic Responders — 2.6; 38.8 percent of participants — p=<0.0001
Phase 2 N=30 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Esophagitis
Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…
N/A N=18 Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
Eosinophilic Gastroenteritis
Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants
Phase 3 N=63 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids
Eosinophilic Esophagitis · Eosinophilic Gastrointestinal Disorders (EGIDs)
Primary: Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks — -14.3; -21.6 units on a scale — p=0.04
Phase 2 N=42 A Study of Flovent in Patients With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Percentage of Participants Who Attained Remission. — 65.2; 0 percentage of participants
Phase 2 N=36 A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Change From Baseline in the Peak Esophageal Intraepithelial Eosinophil Count at Week 4 (Mean) — -9.2; -31.6; -7.8 eosinophil count per high power field
N/A N=22 Cytosponge and Dietary Therapy in EoE
Eosinophilic Esophagitis
Primary: Histological Remission by Sponge Cytology — 13 Participants
N/A N=175 Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation
Atrial Fibrillation
Primary: Incidence of Esophageal Injury as Assessed by Endoscopy — 1; 12; 4; 0 participants
Phase 2 N=66 Mepo for Eosinophilic Esophagitis (EoE) Study
EoE · Eosinophilic Esophagitis
Primary: Mean Change in Dysphagia Score — 15.4; 8.3 score on a scale — p=0.14
N/A N=30 Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
Phase 2 N=15 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Change From Baseline in Peak Eosinophil Count — 63.3; 67.7; 58.9; -11.2 eosinophils per high power field
Phase 4 N=60 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
Barrett's Esophagus · Obesity
Primary: Change in Serum PGE2 Levels — 4.44; -21.65 Percentage of change in serum PGE2 level
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
N/A N=93 Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Esophageal Lesion
Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants
Phase 2 N=59 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
Oesophagitis, Eosinophilic
Primary: Number of Participants With Any Adverse Events (AE), Any Serious Adverse Event (SAE) and Drug-related AE During Treatment Phase (TP) and Follow-up Phase (FP) — 18; 15…
Phase 3 N=337 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Primary: Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N) — 58.8; 78.4; 77.0 Percentage of…
Phase 4 N=305 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
Phase 2 N=90 Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
Esophageal Stricture
Primary: Dysplasia in Barrett Esophagus (BE) — 4; 4; 3; 23 Participants — p=0.992